These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 12756041)
1. Pilot study describing the use of pravastatin in pediatric renal transplant recipients. Butani L; Pai MV; Makker SP Pediatr Transplant; 2003 Jun; 7(3):179-84. PubMed ID: 12756041 [TBL] [Abstract][Full Text] [Related]
2. Prospective monitoring of lipid profiles in children receiving pravastatin preemptively after renal transplantation. Butani L Pediatr Transplant; 2005 Dec; 9(6):746-53. PubMed ID: 16269046 [TBL] [Abstract][Full Text] [Related]
3. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. Seipelt IM; Crawford SE; Rodgers S; Backer C; Mavroudis C; Seipelt RG; Pahl E J Heart Lung Transplant; 2004 Mar; 23(3):317-22. PubMed ID: 15019641 [TBL] [Abstract][Full Text] [Related]
4. The effect of pravastatin on acute rejection after kidney transplantation--a pilot study. Katznelson S; Wilkinson AH; Kobashigawa JA; Wang XM; Chia D; Ozawa M; Zhong HP; Hirata M; Cohen AH; Teraski PI Transplantation; 1996 May; 61(10):1469-74. PubMed ID: 8633373 [TBL] [Abstract][Full Text] [Related]
5. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin. Imagawa DK; Dawson S; Holt CD; Kirk PS; Kaldas FM; Shackleton CR; Seu P; Rudich SM; Kinkhabwala MM; Martin P; Goldstein LI; Murray NG; Terasaki PI; Busuttil RW Transplantation; 1996 Oct; 62(7):934-42. PubMed ID: 8878387 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. Penson MG; Fricker FJ; Thompson JR; Harker K; Williams BJ; Kahler DA; Schowengerdt KO J Heart Lung Transplant; 2001 Jun; 20(6):611-8. PubMed ID: 11404165 [TBL] [Abstract][Full Text] [Related]
7. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Türk TR; Voropaeva E; Kohnle M; Nürnberger J; Philipp T; Kribben A; Heemann U; Witzke O Nephrol Dial Transplant; 2008 Jan; 23(1):369-73. PubMed ID: 17956887 [TBL] [Abstract][Full Text] [Related]
8. Reassuring effect of pravastatin on natural killer cell activity in stable renal transplant patients. Vaessen LM; van Miert PP; van Gelder T; Ijzermans JN; Weimar W Transplantation; 2001 Apr; 71(8):1175-9. PubMed ID: 11374422 [TBL] [Abstract][Full Text] [Related]
9. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP; Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789 [TBL] [Abstract][Full Text] [Related]
10. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. Katznelson S; Wang XM; Chia D; Ozawa M; Zhong HP; Hirata M; Terasaki PI; Kobashigawa JA J Heart Lung Transplant; 1998 Apr; 17(4):335-40. PubMed ID: 9588577 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976 [TBL] [Abstract][Full Text] [Related]
12. Effect of pravastatin in treatment of hypercholesterolemia in non-insulin-dependent diabetes patients. Soonthornpun S; Rattarasarn C; Leelawattana R; Thamprasit A J Med Assoc Thai; 1997 Jan; 80(1):9-15. PubMed ID: 9078811 [TBL] [Abstract][Full Text] [Related]
13. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Yoshimura N; Oka T; Okamoto M; Ohmori Y Transplantation; 1992 Jan; 53(1):94-9. PubMed ID: 1733092 [TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Almutairi F; Peterson TC; Molinari M; Walsh MJ; Alwayn I; Peltekian KM Liver Transpl; 2009 May; 15(5):504-8. PubMed ID: 19399742 [TBL] [Abstract][Full Text] [Related]
15. Effects of pravastatin in heart transplant recipients: implications of Kobashigawa et al. Gotto AM Curr Opin Lipidol; 1995 Dec; 6(6):341-3. PubMed ID: 8750244 [TBL] [Abstract][Full Text] [Related]
16. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia. Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798 [TBL] [Abstract][Full Text] [Related]
17. Low HDL-C predicts the onset of transplant vasculopathy in pediatric cardiac recipients on pravastatin therapy. Hedman M; Pahlman R; Sundvall J; Ehnholm C; Syvänne M; Jokinen E; Jauhiainen M; Holmberg C; Antikainen M Pediatr Transplant; 2007 Aug; 11(5):481-90. PubMed ID: 17631015 [TBL] [Abstract][Full Text] [Related]
18. Hyperlipidemia in pediatric kidney transplant recipients treated with cyclosporine. Chavers BM; Hårdstedt M; Gillingham KJ Pediatr Nephrol; 2003 Jun; 18(6):565-9. PubMed ID: 12712377 [TBL] [Abstract][Full Text] [Related]
19. Impact of fluvastatin on hyperlipidemia after renal transplantation. Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777 [TBL] [Abstract][Full Text] [Related]
20. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Inazu A; Koizumi J; Kajinami K; Kiyohar T; Chichibu K; Mabuchi H Atherosclerosis; 1999 Aug; 145(2):405-13. PubMed ID: 10488970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]